Bioptimus Raises $41M to Advance AI Foundation Model for Biology
Bioptimus’s advanced AI platform bridges the gap between diverse biological datasets and actionable insights, enabling breakthroughs across multiple sectors.
Company Name: Bioptimus
Location: Paris, France
Industry: Health tech
Funding Details:
Amount: $41M
Total Funding: $76M
Investors: Cathay Innovation (Lead), Sofinnova Partners, Bpifrance (Large Venture Fund), Andera Partners, Hitachi Ventures, Boom Capital Ventures, Pomifer Capital, Sunrise, and angel investors Emmanuel Cassimatis and Thomas Wolf
Purpose of Investment:
The funds will be used to:
- Enhance Bioptimus’s multi-modal AI platform by integrating more diverse data sources and therapeutic areas.
- Forge strategic partnerships with pharmaceutical and biotech companies.
- Expand critical datasets to refine and validate its AI models.
Leadership:
CEO: Jean-Philippe Vert
Product:
Bioptimus is building a groundbreaking AI foundation model that connects biology across multiple scales—from molecules to cells, tissues, and entire organisms.
Mission:
The company aims to simulate biological processes and drive innovation for industries such as:
- Medical: Advancing drug discovery and precision medicine.
- Biotech: Creating scalable, data-driven solutions for biological challenges.
- Cosmetics: Innovating product development through biological insights.
About the Company:
Bioptimus’s advanced AI platform bridges the gap between diverse biological datasets and actionable insights, enabling breakthroughs across multiple sectors. Its foundation model represents a pioneering approach to understanding and simulating biology, empowering industries to innovate with unprecedented precision.
With its latest funding, Bioptimus is poised to expand its capabilities and lead the next wave of innovation in biology-powered AI.
